Eikonoklastes Therapeutics Closes Oversubscribed Seed Financing to Advance Next-Generation Tissue Factor (TF) Immunotherapies With Initial Focus on Triple-Negative Breast Cancer July 22, 2020

Published By :
July 21, 2020
email icon in blackFacebook icon in blacktwitter icon in blackLinkedIn icon in black
gradient colors in orange, pink and purple

Recent News & Insights

CincyTech Announces Election of New Board Member and Hiring of Life Sciences Analyst to Drive Innovation and Broader Impact

Featured News
·
November 19, 2024

Ohio Life Sciences Appoints Five New Board Members

Featured News
·
November 15, 2024

St. Elizabeth Healthcare Partners with CincyTech to Advance Healthcare Innovation & Improve Patient Outcomes

Featured News
·
November 4, 2024
More News And Insights
Subscribe TO our newsletter

Stay Up To Date With Our News & Insights

Stay informed with current news about our portfolio companies, events and industry insights.
email icon in gradient orange, pink and purple colors
You are subscribed to our newsletters
Oops! Something went wrong while submitting the form.
CincyTech is a venture capital firm that invests in innovative founders tackling the world's complex challenges. Our experienced team is fluent in the language of founders, researchers, and inventors working with deep domain expertise and market foresight. We partner early to help transform ideas into world-class companies.
2900 Reading Rd. Ste. 410 Cincinnati, OH 45206
Contact CincyTech
Twitter icon in white
Cincytech logo
HomeApproachPortfolioTeamCommunityNews & InsightsPitch Us
© 2023 Copyright - CincyTech
CareersUniversity ProgramsDisclosures
Made by 5Four Digital®